|
The Implementing Act has been officially published in the Official Journal as of 27 November 2025
|
|---|
Important Deadlines for Medical Device Manufacturers:
The following EUDAMED modules are now active:
|
INTRODUCTION
The EU’s regulatory landscape for medical devices and In Vitro Diagnostic devices (IVDs) is far from a “set it and forget it” system. While manufacturers have the internal obligation of Post-Market Surveillance (PMS), the EU Market Surveillance system is the external mechanism ensuring public health and product safety. It’s the ultimate check performed by national authorities, and it has fundamentally changed how medical device manufacturers operate under the MDR (Medical Device Regulation) and IVDR (In Vitro Diagnostic Regulation).
WHAT MARKET SURVEILLANCE MEANS FOR YOU (IT'S NOT JUST AN AUDIT)
Market Surveillance refers to the independent actions taken by EU Member State authorities to quickly detect and eliminate non-compliant, hazardous, or counterfeit medical devices from the market.
Think of it this way:
- PMS (Post-Market Surveillance) is the manufacturer proactively self-monitoring their device (internal check).
- Vigilance is the system for reporting serious incidents (reacting to risks).
- Market Surveillance is the EU’s “police force,” conducting external inspections and demanding documentation to ensure you are doing both of the above correctly.
The ultimate impact is that the regulatory spotlight has shifted from just initial certification to the entire life cycle of your product on the market.
THE REAL IMPACT ON MANUFACTURERS: SPEED, INTEGRATION, AND CONSEQUENCES
For every medical device and IVD manufacturer, the MDR/IVDR framework tightens the screws on compliance, demanding a faster, more integrated, and transparent approach. Here’s how this guidance directly impacts your day-to-day operations:
1. The Need for Speed is modification
The most crucial change is the dramatic reduction in incident reporting timelines. Under the MDR/IVDR, the deadline for reporting serious incidents (known as Vigilance) to the authorities has been slashed from 30 days down to a maximum of 15 calendar days after detection.
- Manufacturer Impact: This reduced timeline means your internal teams (Regulatory, Quality, and R&D) must have instant, well-documented procedures for incident classification and reporting. A delay of just a few days can result in non-compliance.
2. EUDAMED is the New Central Hub
The European Database on Medical Devices (EUDAMED) is the central information system. All vigilance reports and Field Safety Corrective Actions (FSCA) must be submitted here, bypassing former national reporting systems.
- Manufacturer Impact: You must be proficient in using EUDAMED. It provides a real-time, transparent view of product safety trends to all authorities. If you are slow or inaccurate, authorities conducting market surveillance will spot it immediately.
3. Non-Serious Trends are Now Serious Business
Previously, reporting often focused only on serious incidents. Now, manufacturers are explicitly obligated to monitor and analyze significant trends in non-serious incidents and product malfunctions.
- Manufacturer Impact: Your Quality Management System (QMS) must be robust enough to conduct continuous data analysis and statistical trend assessment. This data must then trigger a Corrective and Preventive Action (CAPA) process, which is integrated with your QMS and technical documentation (aligned with ISO 13485).
4. The Price of Non-Compliance is High
Cooperation with market surveillance authorities is mandatory. Failure to cooperate or being found non-compliant during an inspection can lead to severe consequences:
- Fines and Administrative Penalties.
- Mandatory Product Recalls or Withdrawals.
- Revocation of your CE Certificate.
- Temporary suspension of business operations.
THE REGULATIONS
Your primary reference for the requirements of Market Surveillance is the core legislation:
Article 93 of the Medical Device Regulation (MDR) (EU 2017/745) and Article 88 of the IVD Regulation (IVDR) (EU 2017/746):
- These articles define what Market Surveillance is—the checks performed by Competent Authorities (CAs) on devices already on the market.
- They detail the CAs’ powers, such as requiring documentation, conducting announced or unannounced inspections of manufacturers/suppliers, and taking action against non-compliant or risky devices.
- These articles define what Market Surveillance is—the checks performed by Competent Authorities (CAs) on devices already on the market.
EUDAMED-SPECIFIC GUIDANCE
Here is the essential guidance for manufacturers related to Market Surveillance and EUDAMED:
- EUDAMED User Guide for the Market Surveillance Module: While focused on CAs, this user guide is invaluable for manufacturers because it shows what information CAs are collecting and how they are using the system to coordinate. Understanding this helps you anticipate their requests.
- MDCG Guidance on EUDAMED Functionality: Documents like MDCG 2021-1 (Rev. 1) and MDCG 2022-12 cover the transitional arrangements and how to report data to national systems until all EUDAMED modules become mandatory.
CONCLUSION
The EU Market Surveillance system demands that medical device and IVD manufacturers adopt a highly proactive approach to compliance. Under the MDR/IVDR, this external enforcement mechanism requires manufacturers to dramatically speed up their incident reporting to a maximum of 15 days for serious incidents and to ensure transparent data submission via EUDAMED. Success hinges on seamlessly integrating Post-Market Surveillance (PMS) with a robust Quality Management System (QMS). Failure to maintain these stringent standards and cooperate fully with authorities can result in severe consequences, including mandatory product recalls and the revocation of the CE marking.
HOW MORULAA CAN HELP
At Morulaa, we specialize in helping global medical device and IVD manufacturers navigate EU regulatory requirements from CE marking and PMS planning to EUDAMED registrations and post-market vigilance. With our expert guidance, you stay compliant, audit-ready, and confident in your market presence. Whether you’re launching or scaling in Europe, Morulaa ensures you meet regulatory expectations without the overwhelm.